Can radiation kickstart the immune system against stubborn GI cancers?

NCT ID NCT04221893

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiation while continuing their current immunotherapy. The goal is to slow or stop cancer progression and improve treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC ANAL CANAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC ANAL CANAL CARCINOMA METASTATIC COLORECTAL CARCINOMA METASTATIC ESOPHAGEAL CARCINOMA METASTATIC GASTRIC CARCINOMA METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA METASTATIC HEPATOCELLULAR CARCINOMA METASTATIC MALIGNANT DIGESTIVE SYSTEM NEOPLASM METASTATIC SMALL INTESTINAL CARCINOMA PANCREATOBILIARY CARCINOMA PATHOLOGIC STAGE IV GASTRIC CANCER AJCC V8 PATHOLOGIC STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IVA ESOPHAGEAL SQUAMOUS CELL CARCINOMA AJCC V8 PATHOLOGIC STAGE IVB ESOPHAGEAL ADENOCARCINOMA AJCC V8 PATHOLOGIC STAGE IVB ESOPHAGEAL SQUAMOUS CELL CARCINOMA AJCC V8 PATHOLOGIC STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IV ESOPHAGEAL SQUAMOUS CELL CARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IV GASTRIC CANCER AJCC V8 POSTNEOADJUVANT THERAPY STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVA ESOPHAGEAL SQUAMOUS CELL CARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVB ESOPHAGEAL ADENOCARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVB ESOPHAGEAL SQUAMOUS CELL CARCINOMA AJCC V8 POSTNEOADJUVANT THERAPY STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 STAGE IV ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION STAGE IV ANAL CANCER AJCC V8 STAGE IV COLORECTAL CANCER AJCC V8 STAGE IV ESOPHAGEAL ADENOCARCINOMA STAGE IV ESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE IV GASTRIC CANCER STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IVA ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION STAGE IVA COLORECTAL CANCER AJCC V8 STAGE IVA ESOPHAGEAL ADENOCARCINOMA STAGE IVA ESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE IVA GASTRIC CANCER STAGE IVA HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IVB COLORECTAL CANCER AJCC V8 STAGE IVB ESOPHAGEAL ADENOCARCINOMA STAGE IVB ESOPHAGEAL SQUAMOUS CELL CARCINOMA STAGE IVB GASTRIC CANCER STAGE IVB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA STAGE IVB HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IVC COLORECTAL CANCER AJCC V8

Contacts and locations

Locations

  • John Muir Medical Center-Walnut Creek

    NOT_YET_RECRUITING

    Walnut Creek, California, 94598, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.